Lurbinectedin is a medication that has been approved by the FDA for the treatment of metastatic small cell lung cancer (SCLC) in patients who have received prior treatment. While it has shown promising results in clinical trials, there are some limitations to its use.

One limitation of lurbinectedin is its potential side effects. The FDA has listed several warnings and precautions in the drug's label [3], including the risk of myelosuppression, which can lead to infections and bleeding, as well as hepatotoxicity, which can cause liver damage. Other potential side effects include fatigue, nausea, and vomiting [2].

Another limitation of lurbinectedin is its narrow indication. As of now, the drug has only been approved for the treatment of metastatic SCLC in patients who have received prior treatment. It is not approved for use in other types of cancer or as a first-line treatment for SCLC [3].

Additionally, the cost of lurbinectedin may be a limitation for some patients. According to Drug Patent Watch [1], the drug is currently under patent protection, which may make it more expensive than other treatment options.

In conclusion, while lurbinectedin has shown promise in treating metastatic SCLC, there are limitations to its use, including potential side effects, a narrow indication, and cost. Patients should discuss the risks and benefits of this medication with their healthcare provider to determine if it is the right treatment option for them.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf